Acceleration of HIV dementia with methamphetamine and cocaine

References

• Aweeka F, Jayewardene A, Staprans S, Bellibas SE, Kearney B, Lizak P. Novakovic-Agopian T, Price RW (1999). Failure to detect nelfinavir in the cerebrosp-inal fluid of HIV-I-infected patients with and without AIDS dementia complex. I Acquir Immune Defic Syndr Hum Retrovirol 20: 39–43.
   Google Scholar
• Bell JE, Brettle RP, Chiswick A, Simmonds P (1998). HIV encephalitis, proviral load and dementia in drug users and homosexuals with AIDS. Effect of neocortical involvement. Brain 121: 2043–2052.
   PubMed Web of Science ®Google Scholar
• Berger JR, Kumar M, Kumar A, Fernandez JB, Levin B (1994). Cerebrospinal fluid dopamine in HIV-1 infec-tion. AIDS 8: 67–71.
   PubMed Web of Science ®Google Scholar
• Berger JR, Nath A (1997). HIV dementia and the basal ganglia. Intervirology 40: 122–131.
   PubMedGoogle Scholar
• Berger JR, Nath A, Greenberg RN, Andersen AH, Greene RA, Bognar A, Avison MJ (2000). Cerebrovascular changes in the basal ganglia with HIV dementia. Neurology 54: 921–926.
   PubMed Web of Science ®Google Scholar
• Bouwman FH, Skolasky RL, Hes D, Selnes OA, Glass JD, Nance-Sproson TE, Royal W, Dal Pan GJ, McArthur JC (1998). Variable progression of HIV-associated demen-tia. Neurology 50: 1814–1820.
   PubMed Web of Science ®Google Scholar
• Concha M, Graham NM, Munoz A, Vlahov D, Royal WD, Updike M, Nance-Sproson T, Selnes OA, McArthur JC (1992). Effect of chronic substance abuse on the neuropyschological performance of intravenous drug users with a high prevalence of HIV-1 seropositivity. Am I Epidemiol 136: 1338–1348.
   PubMed Web of Science ®Google Scholar
• Concha M, Selnes OA, Vlahov D, Nance-Sproson T, Updike M, Royal W, Palenicek I, McArthur IC (1997). Comparison of neuropsychological performance be-tween AIDS-free injecting drug users and homosexual men. Neuroepidemiology 16: 78–85.
   PubMed Web of Science ®Google Scholar
• Ernst T, Chang L, Leonido-Yee M, Speck 0 (2000). Evidence of long term neurotoxicity associated with methamphetamine abuse. A 1H MRS study. Neurology 54: 1344–1349.
   Google Scholar
• Fiala M, Gan XH, Zhang L, House SD, Newton T, Graves MC, Shapshak P, Stins M, Kim KS, Witte M, Chang SL (1998). Cocaine enhances monocyte migration across the blood-brain barrier. Cocaine's connection to AIDS dementia and vasculitis? Adv Exp Med Biol 437: 199–205.
   PubMedGoogle Scholar
• Fujimura RK, Goodkin K, Petito UK, Douyon R, Feaster DJ, Concha M, Shapshak P (1997). 1-1IV-1 proviral DNA load across neuroanatomic regions of indivi-duals with evidence for HIV-I-associated dementia. I Acquir Immune Defic Syndr Hum Retrovirol 16: 146–152.
   PubMedGoogle Scholar
• Gendelman H, Meng I, Coulter C, Ghorpade A, Che M, Thylin M, Rubocki R, Persidsky Y, Hahn F, Reinhard I, Swindells S (1998). The HIV-associated dementia complex: a metabolic encephalopathy reversed by highly active antiretroviral therapy. I Infect Dis 178: 1000–1007.
   PubMed Web of Science ®Google Scholar
• Grassi MP, Perin C, Clerici F, Zocchetti C, Borella M, Cargnel A, Mangoni A (1997). Effects of HIV seropositivity and drug abuse on cognitive function. Eur Neurol 37: 48–52.
   PubMed Web of Science ®Google Scholar
• Harrison MB, Lyons GR, Landow ER (1993). Phenytoin and dyskinesias: a report of two cases and review of the literature. Mov Disord 8: 19–27.
   PubMed Web of Science ®Google Scholar
• Hayman M, Arbuthnott G, Harkiss G, Brace H, Filippi P, Philippon V, Thomson D, Vigne R, Wright A (1993). Neurotoxicity of peptide analogues of the transactivat-ing protein tat from Maedia-Visna virus and human immunodeficiency virus. Neuroscience 53: 1–6.
   PubMed Web of Science ®Google Scholar
• Hofman FM, Dohadwala MM, Wright AD, Hinton DR, Walker SM (1994). Exogenous tat protein activates central nervous system-derived endothelial cells. I Neuroimmunol 54: 19–28.
   PubMed Web of Science ®Google Scholar
• Jones M, Olafson K, Del Bigio MR, Peeling I, Nath A (1998). Intraventricular injection of human immuno-deficiency virus type 1 (HIV-I) Tat protein causes inflammation, gliosis, apoptosis, and ventricular en-largement. I Neuropathol Exp Neurol 57: 563–570.
   PubMed Web of Science ®Google Scholar
• Kruman II, Nath A, Maragos WF, Chan SL, Jones M, Rangnekar VM, Jakel RI, Mattson MP (1999). Evidence that Par-4 participates in the pathogenesis of AIDS dementia. Am I Pathol 155: 39–46.
   Google Scholar
• Langston JW, Forno LS, Tetrud I, Reeves AG, Kaplan JA, Karluk D (1999). Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine ex-posure. Ann Neurol 46: 598–605.
   Google Scholar
• Larsson M, Hagberg L, Forsman A, Norkrans G (1991). Cerebrospinal fluid catecholamine metabolites in hIV-infected patients. I Neurosci Res 28: 406–409.
   PubMed Web of Science ®Google Scholar
• Nath A, Conant K, Chen P, Scott C, Major EO (1999). Transient exposure to HIV-1 Tat protein results in cytokine production in macrophages and astrocytes: A hit and run phenomenon. I Biol Chem 274: 17098–17102.
   Google Scholar
• Nath A, Geiger JD (1998). Neurobiological aspects of HIV infections: neurotoxic mechanisms. Prog Neurobiol 54: 19–33.
   PubMed Web of Science ®Google Scholar
• Nath A, Haughey NJ, Jones M, Anderson C, Bell JE, Geiger JD (2000). Synergistic neurotoxicity by human immunodeficiency virus proteins Tat and gp120: protection by memantine. Ann Neurol 47: 186–194.
   PubMed Web of Science ®Google Scholar
• Nath A, Jones M, W, M, Booze RM, Mactutus C, Bell J, Mattson M (2000). Neurotoxicity and Dysfunction of Dopaminergic Systems Associated with AIDS Demen-tia. I Psychopharmacology (in press).
   Google Scholar
• Navia BA, Cho ES, Petiio UK, Price RW (1986). The AIDS dementia complex: II Neuropathology. Ann Neurol 19, 525–535.
   PubMed Web of Science ®Google Scholar
• Power C, McArthur IC, Johnson RT, Griffin DE, Glass JD, Perryman S, Chesebro B (1994). Demented and nondemented patients with AIDS differ in brain-derived human immunodeficiency virus type 1 envelope sequences. I Virol 68: 4643–4649.
   PubMed Web of Science ®Google Scholar
• Power C, Selnes OA, Grim JA, McArthur IC (1995). HIV Dementia Scale: a rapid screening test. I Acquir Immune Defic Syndr Hum Retrovirol 8: 273–278.
   PubMed Web of Science ®Google Scholar
• Price RW, Brew BJ (1988). The AIDS dementia complex. I Infect Dis 158: 1079–1083.
   PubMed Web of Science ®Google Scholar
• Price RW, Yiannoutsos CT, Clifford DB, Zaborski L, Tselis A, Sidtis JJ, Cohen B, Hall CD, Erice A, Henry K (1999). Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survi-val and protective effect of antiviral therapy. AIDS Clinical Trial Group and Neurological AIDS Research Consortium study team. AIDS 13: 1677–1685.
   Google Scholar
• Reyes MG, Faraldi F, Senseng CS, Flowers C, Fariello R (1991). Nigral degeneration in acquired immune deficiency syndrome (AIDS). Acta Neuropathol 82: 39–44.
   PubMed Web of Science ®Google Scholar
• Sacktor NC, Lyles RH, Skolasky RL, Anderson DE, McArthur JC, McFarlane G, Selnes OA, Becker IT, Cohen B, Wesch I, Miller EN (1999). Combination antiretroviral therapy improves psychomotor speed performance in HEV-seropositive homosexual men. Multicenter AIDS Cohort Study (MACS). Neurology 52: 1640–1647.
   Google Scholar
• Sardar AM, Czudek C, Reynolds GP (1996). Dopamine deficits in the brain: the neurochemical basis of parkinsonian symptoms in AIDS. Neuro report 7: 910–912.
   Google Scholar
• Selnes OA, Galai N, McArthur IC, Cohn S, Royal W, 3rd, Esposito D, Vlahov D (1997). HIV infection and cognition in intravenous drug users: long-term fol-low-up. Neurology 48: 223–230.
   Google Scholar
• Villemagne V, Yuan I, Wong DF, Dannals RF, Hatzidimi-triou G, Mathews WB, Ravert HT, Musachio I, McCann UD, Ricaurte GA (1998). Brain dopamine neurotoxicity in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans: evidence from [11C1WIN-35,428 positron emission tomography studies and direct in vitro determinations. I Neurosci 18: 419–427.
   Google Scholar
• Wilson JM, Kalasinsky KS, Levey Al, Bergeron C, Reiber G, Anthony RM, Schmunk GA, Shannak K, Haycock JW, Kish SJ (1996a). Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 2: 699–703.
   PubMed Web of Science ®Google Scholar
• Wilson JM, Levey Al, Bergeron C, Kalasinsky K, Ang L, Peretti F, Adams VI, Smialek I, Anderson WR, Shannak K, Deck I, Niznik HB, Kish SJ (1996b). Striatal dopamine, dopamine transporter, and vesicu-lar monoamine transporter in chronic cocaine users. Ann Neurol 40: 428–439.
   PubMed Web of Science ®Google Scholar